Entries / intervention
Menopausal hormone therapy
moderate Evidence strength · Status: published · Source agreement: medium
Not medical advice
Menowise aggregates and organizes what the published literature reports, with citations. It does not diagnose, advise, or recommend treatment. Talk to a qualified clinician about your own care.
What the literature reports
Menopausal hormone therapy (MHT; also called HRT or hormone replacement therapy) is addressed in The Menopause Society's 2022 Hormone Therapy Position Statement, which reports that hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture. The statement reports that for women younger than 60 years or within 10 years of menopause onset and without contraindications, the benefit-risk ratio is favorable for treating bothersome VMS and preventing bone loss. It also reports that for women who initiate hormone therapy more than 10 years from menopause onset or who are older than 60, the benefit-risk ratio appears less favorable, with greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. This entry summarizes what the literature reports for navigation and is not medical advice.
Citations
-
The Menopause Society — 2022 Hormone Therapy Position Statement (Menopause, 2022) — The Menopause Society (Menopause journal) (2022)
Effectiveness for VMS/GSM and bone; timing-dependent benefit-risk (early vs. late initiation).
Notes
Maps to entities.yml `menopausal-hormone-therapy` (intervention); the id reuses the canonical entity id rather than re-slugging to `hormone-therapy`, keeping record and entity aligned and stable across runs. All three signals derive from a single source (The Menopause Society 2022 HT Position Statement), so confidence is medium. evidence_strength: moderate — a professional-society position statement synthesizing graded evidence; the underlying trials/meta-analyses are not directly cited. The timing-hypothesis benefit-risk distinction (early vs. late initiation) is a facet kept within this single intervention entry. Vasomotor symptoms and GSM are separate symptom entries and cross-referenced there.
Provenance
This entry is resolved from per-source signals; the raw claims are the audit trail behind it.
- Machine record: /data/sites/menopausal-hormone-therapy.yml (schema-valid, verbatim)
- Signals:
sig-20260710-hormone-therapy-guideline-recommendation,sig-20260710-hormone-therapy-early-benefit-risk,sig-20260710-hormone-therapy-late-initiation-safety - First recorded 2026-07-10 · last updated 2026-07-10